[go: up one dir, main page]

MX2023009955A - Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas. - Google Patents

Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.

Info

Publication number
MX2023009955A
MX2023009955A MX2023009955A MX2023009955A MX2023009955A MX 2023009955 A MX2023009955 A MX 2023009955A MX 2023009955 A MX2023009955 A MX 2023009955A MX 2023009955 A MX2023009955 A MX 2023009955A MX 2023009955 A MX2023009955 A MX 2023009955A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
present
ophthalmic pharmaceutical
preparation
methods
Prior art date
Application number
MX2023009955A
Other languages
English (en)
Inventor
Hau Juan De Dios Quintana
Hurtado Paulina Chávez
Alejo Juan Manuel Martinez
Original Assignee
Sophia Holdings S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sophia Holdings S A De C V filed Critical Sophia Holdings S A De C V
Priority to MX2023009955A priority Critical patent/MX2023009955A/es
Priority to PCT/IB2023/058631 priority patent/WO2025040941A1/en
Publication of MX2023009955A publication Critical patent/MX2023009955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas oftálmicas para el control de la presión intraocular (PIO) preparados a través de un método que consiste en tratar a los principios activos conocidos y/o sus sales para permitir su acomplejamiento con diferentes matrices. Estos sistemas generan productos finales que son estables, y que permiten el uso de ingredientes farmacéuticos activos (APIs) a concentraciones nunca antes exploradas a valores de pH críticos; además de mantener una biodisponibilidad adecuada, y evitar los efectos secundarios conocidos colectivamente como "sensación de ardor".
MX2023009955A 2023-08-24 2023-08-24 Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas. MX2023009955A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2023009955A MX2023009955A (es) 2023-08-24 2023-08-24 Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.
PCT/IB2023/058631 WO2025040941A1 (en) 2023-08-24 2023-08-31 Ophthalmic pharmaceutical compositions containing dorzolamide, methods for their preparation, and for their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2023009955A MX2023009955A (es) 2023-08-24 2023-08-24 Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.

Publications (1)

Publication Number Publication Date
MX2023009955A true MX2023009955A (es) 2025-03-07

Family

ID=94731620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009955A MX2023009955A (es) 2023-08-24 2023-08-24 Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.

Country Status (2)

Country Link
MX (1) MX2023009955A (es)
WO (1) WO2025040941A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
KR20150031340A (ko) * 2010-07-15 2015-03-23 코린시언 아프샐믹 인코포레이티드 안과용 약물 전달
US20130053425A1 (en) * 2011-08-30 2013-02-28 Chi-Ho To Method for Lowering Intraocular Pressure Using Gap Junction Blockers
WO2017210130A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
CN112972683A (zh) * 2019-12-13 2021-06-18 刘力 局部给药的葛林佐胺等药物组合物

Also Published As

Publication number Publication date
WO2025040941A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
ES2095566T3 (es) Suspension farmaceutica acuosa para agentes activos farmaceuticos.
JP6934682B2 (ja) 細胞培養培地中に有効成分として、アルブミン、ヒアルロン酸またはコラーゲンを含む化粧品組成物
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
EP4438034A3 (en) Injectable formulation
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
EP2263648B1 (en) Ophthalmic composition
BR112013003934A2 (pt) depot de fosfolipídeos
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
RU2010117173A (ru) Глазные композиции на основе полисахарида семян тамаринда и гиалуроновой кислоты
NZ591205A (en) Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
KR100260061B1 (en) Vitamin e drop
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
CR20220457A (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
FI3445331T3 (fi) Säilöntäainevapaita farmaseuttisia oftalmisia koostumuksia
MX2023009955A (es) Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
MY207295A (en) Method for preparing a composition comprising cetylated fatty acids
WO2022056220A3 (en) Excipient compounds for protein formulations
CN109549864B (zh) 一种乳化型祛斑化妆品及其制备方法
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
AU2020299145A8 (en) Compositions and methods for treating eye diseases
FI4182311T3 (fi) 1-metyyli-1h-pyratsol-3-yyli johdannaiset käyttöön neovaskulaaristen sairauksien hoidossa
RU2019118904A (ru) Распределение в глазу и фармакокинетика композиций лифитеграста
MX2022009934A (es) Composicion farmaceutica que comprende esomeprazol y bicarbonato de sodio con excelentes propiedades de liberacion.
WO2007078848A3 (en) Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid